27 February 2026
Lilly's Olumiant Gains CHMP Nod for Adolescent Alopecia Areata in EU
CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.
